| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
Adenylosuccinic acid manufacturers
|
| | Adenylosuccinic acid Basic information |
| Product Name: | Adenylosuccinic acid | | Synonyms: | ADENYLOSUCCINIC ACID HYDRATE;2-[[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid;adenylosuccnic acid;adenylosuccinic acid free acid;aspartyl adenylate;Aspartyl-AMP;L-Aspartic acid 4-(5'-adenylyl) ester;N-[9-(5-O-Phosphono-β-D-ribofuranosyl)-9H-purin-6-yl]-L-aspartic acid | | CAS: | 19046-78-7 | | MF: | C14H18N5O11P | | MW: | 463.29 | | EINECS: | | | Product Categories: | Activity;Chromogenic;Enzyme Substrates;API | | Mol File: | 19046-78-7.mol |  |
| | Adenylosuccinic acid Chemical Properties |
| Boiling point | 921.9±75.0 °C(Predicted) | | density | 2.19±0.1 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | DMF: 20 mg/ml
DMSO: 20 mg/ml
Ethanol: Partially solublePBS (pH 7.2): 10 mg/ml | | pka | 1.86±0.10(Predicted) | | form | powder | | color | White to off-white | | InChIKey | OFBHPPMPBOJXRT-VWJPMABRSA-N | | SMILES | O[C@H]1[C@@H](O)[C@@H](O[C@@H]1COP(O)(O)=O)n2cnc3c(N[C@@H](CC(O)=O)C(O)=O)ncnc23 |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | Adenylosuccinic acid Usage And Synthesis |
| Uses | Adenylosuccinic acid (Adenylosuccinate; Aspartyl adenylate) is a purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid has the potential for the study of duchenne muscular dystrophy(DMD)[1]. | | Definition | ChEBI: The N6-(1,2-dicarboxyethyl) derivative of adenosine 5'-monophosphate. | | in vivo | Adenylosuccinic acid (oral administration; 3-3000 μg/mL; 6 weeks) significantly improves the features of murine DMD, it decreases the number of centronucleated fibres, lipid accumulation, connective tissue infiltration and Ca2+content of mdx tibialis anterior[1]. | Animal Model: | C57Bl/10ScSn (normal wild-type strain; Con)and C57Bl/10mdx(mdx) mice[1] | | Dosage: | 3μg/mL, 30μg/mL, 300μg/mL, 3000 μg/mL | | Administration: | 3μg/mL for 3 days and 30μg/mL for the next 4 days, and 300μg/mL for one week, and then 3000μg/mL for 6 weeks | | Result: | Ameliorated the symptoms of murine duchenne muscular dystrophy.
|
| | IC 50 | Human Endogenous Metabolite | | References | [1] Timpani CA, et al. Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy.Sci Rep. 2020 Jan 24;10(1):1125. DOI:10.1038/s41598-020-57610-w
[2] WAARDE A V. OPERATION OF THE PURINE NUCLEOTIDE CYCLE IN ANIMAL TISSUES[J]. Biological Reviews, 1988, 63 2: 259-298. DOI: 10.1111/j.1469-185x.1988.tb00632.x
[3] HALONEN J, NEDERGAARD J. Adenosine 5-Monophosphate Is a Selective Inhibitor of the Brown Adipocyte Nonselective Cation Channel[J]. The Journal of Membrane Biology, 2002, 14 1: 0. DOI: 10.1007/s00232-001-0184-0
[4] Y. NISHIDA T. M. Contractile effect of succinylpurines on guinea pig uterus[J]. General Pharmacology-the Vascular System, 1988, 19 2: Pages 277-279. DOI: 10.1016/0306-3623(88)90076-6
[5] JESSICA R GOODING. Adenylosuccinate Is an Insulin Secretagogue Derived from Glucose-Induced Purine Metabolism.[J]. Cell reports, 2015, 13 1: 157-167. DOI: 10.1016/j.celrep.2015.08.072
[6] TARAKA R. DONTI . Diagnosis of adenylosuccinate lyase deficiency by metabolomic profiling in plasma reveals a phenotypic spectrum[J]. Molecular Genetics and Metabolism Reports, 2016, 8: Pages 61-66. DOI: 10.1016/j.ymgmr.2016.07.007 |
| | Adenylosuccinic acid Preparation Products And Raw materials |
|